Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Iambic Therapeutics, Inc.IAM · Entity 184417 | CFO & Chief Corp Dev Ofcr | October 14, 2026 | October 14, 2026 |
| RECURSION PHARMACEUTICALS, INC.RXRX · Entity 1008 | Chief Financial Officer | November 15, 2024 | November 19, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Iambic Therapeutics, Inc.
Report date October 14, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 190,160 |
Reported balance
Holding disclosure · report date 2026-10-14 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 190,160 F1: Of the reported shares, 23,770 were issued pursuant to an early exercise provision and which vest in full on January 1, 2027. |
| Series B-3 Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-10-14 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: Each share of Series B-3 Convertible Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.31 · Expires 2035-01-08 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-10-14 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: An option to purchase 380,322 shares was granted on January 8, 2025 and was exercised in part prior to the date on which the reporting person became subject to Section 16. The option is subject to an early exercise provision and is immediately exercisable. The shares subject to the option vest in 48 equal monthly installments beginning on February 1, 2025. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.73 · Expires 2036-03-03 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-10-14 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: The shares subject to the option vest in 48 equal monthly installments beginning on March 23, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Of the reported shares, 23,770 were issued pursuant to an early exercise provision and which vest in full on January 1, 2027.
F2: Each share of Series B-3 Convertible Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.
F3: An option to purchase 380,322 shares was granted on January 8, 2025 and was exercised in part prior to the date on which the reporting person became subject to Section 16. The option is subject to an early exercise provision and is immediately exercisable. The shares subject to the option vest in 48 equal monthly installments beginning on February 1, 2025.
F4: The shares subject to the option vest in 48 equal monthly installments beginning on March 23, 2026.
RECURSION PHARMACEUTICALS, INC.
Report date November 15, 2024 · Filed November 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 1,487,694 |
Reported balance
After 2024-11-15 transaction · row 1
1 source rowRow 1 · 2024-11-15 · Tax withholding · Disposed 11,937 · Balance 1,487,694 F1: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.22 · Expires 2030-03-03 | Direct | 337,635 |
Reported balance
Holding disclosure · report date 2024-11-15 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 337,635 F2: The option, originally for 1,500,000 shares, vests incrementally upon satisfaction of certain liquidity events. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.22 · Expires 2030-03-03 | Direct | 685,177 |
Reported balance
Holding disclosure · report date 2024-11-15 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 685,177 F3: The option, originally for 1,125,000 shares, vests as to one forty-eighth (1/48th) of the shares subject to the award one month after March 1, 2020, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.40 · Expires 2032-02-04 | Direct | 3,914 |
Reported balance
Holding disclosure · report date 2024-11-15 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 3,914 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.40 · Expires 2032-02-04 | Direct | 116,684 |
Reported balance
Holding disclosure · report date 2024-11-15 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 116,684 F4: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.55 · Expires 2033-02-01 | Direct | 404,857 |
Reported balance
Holding disclosure · report date 2024-11-15 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 404,857 F5: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.09 · Expires 2034-02-09 | Direct | 348,380 |
Reported balance
Holding disclosure · report date 2024-11-15 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 348,380 F6: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F2: The option, originally for 1,500,000 shares, vests incrementally upon satisfaction of certain liquidity events.
F3: The option, originally for 1,125,000 shares, vests as to one forty-eighth (1/48th) of the shares subject to the award one month after March 1, 2020, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter.
F4: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F5: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F6: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2023 Filed Aug 17, 2023 22:35 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 37,500 | $2.22 | $83,250.00 |
DisclosureSEC source: 0001209191-23-046423 · doc4.xml · nonDerivative · entry 2 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 875,686 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2023. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 22:35 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 4,727 | $9.19 | $43,441.13 |
DisclosureSEC source: 0001209191-23-046423 · doc4.xml · nonDerivative · entry 1 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 838,186 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| July 19, 2023 Filed Jul 19, 2023 23:07 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-23-042798 · doc4.xml · derivative · entry 9 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 670,313 Underlying: Class A Common Stock · 37,500 shares Expires 2030-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2023. F7 · derivative.exercise_date: The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. Read SEC document |
| July 19, 2023 Filed Jul 19, 2023 23:07 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 9,859 | $16.00 | $157,734.14 |
DisclosureSEC source: 0001209191-23-042798 · doc4.xml · nonDerivative · entry 7 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 842,913 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2023. F6 · price: This transaction was executed in multiple trades at prices ranging from $15.78 to $16.66. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 19, 2023 Filed Jul 19, 2023 23:07 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 13,150 | $15.36 | $202,018.19 |
DisclosureSEC source: 0001209191-23-042798 · doc4.xml · nonDerivative · entry 6 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 852,772 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2023. F5 · price: This transaction was executed in multiple trades at prices ranging from $14.78 to $15.77. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 19, 2023 Filed Jul 19, 2023 23:07 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 1,991 | $14.36 | $28,595.94 |
DisclosureSEC source: 0001209191-23-042798 · doc4.xml · nonDerivative · entry 5 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 865,922 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $13.78 to $14.76. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 19, 2023 Filed Jul 19, 2023 23:07 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 37,500 | $2.22 | $83,250.00 |
DisclosureSEC source: 0001209191-23-042798 · doc4.xml · nonDerivative · entry 4 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 867,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2023. Read SEC document |
| July 18, 2023 Filed Jul 19, 2023 23:07 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-23-042798 · doc4.xml · derivative · entry 8 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 707,813 Underlying: Class A Common Stock · 37,500 shares Expires 2030-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2023. F7 · derivative.exercise_date: The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. Read SEC document |
| July 18, 2023 Filed Jul 19, 2023 23:07 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 500 | $14.05 | $7,024.00 |
DisclosureSEC source: 0001209191-23-042798 · doc4.xml · nonDerivative · entry 3 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 830,413 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $14.01 to $14.09. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 18, 2023 Filed Jul 19, 2023 23:07 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 24,500 | $13.62 | $333,778.20 |
DisclosureSEC source: 0001209191-23-042798 · doc4.xml · nonDerivative · entry 2 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 830,913 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.00 to $13.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 18, 2023 Filed Jul 19, 2023 23:07 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 37,500 | $2.22 | $83,250.00 |
DisclosureSEC source: 0001209191-23-042798 · doc4.xml · nonDerivative · entry 1 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 855,413 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2023. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 23:28 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-23-037582 · doc4.xml · derivative · entry 6 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 745,313 Underlying: Class A Common Stock · 37,500 shares Expires 2030-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2023. F5 · derivative.exercise_date: The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 23:28 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 25,000 | $10.07 | $251,837.50 |
DisclosureSEC source: 0001209191-23-037582 · doc4.xml · nonDerivative · entry 4 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 817,913 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $9.63 to $10.44. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 23:28 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 37,500 | $2.22 | $83,250.00 |
DisclosureSEC source: 0001209191-23-037582 · doc4.xml · nonDerivative · entry 3 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 842,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2023. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 23:28 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-23-037582 · doc4.xml · derivative · entry 5 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 782,813 Underlying: Class A Common Stock · 37,500 shares Expires 2030-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2023. F5 · derivative.exercise_date: The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 23:28 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 25,000 | $9.93 | $248,307.50 |
DisclosureSEC source: 0001209191-23-037582 · doc4.xml · nonDerivative · entry 2 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 805,413 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $9.59 to $10.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 23:28 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 37,500 | $2.22 | $83,250.00 |
DisclosureSEC source: 0001209191-23-037582 · doc4.xml · nonDerivative · entry 1 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 830,413 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2023. F2 · balance_after: Includes 2,754 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on May 22, 2023. Read SEC document |
| May 15, 2023 Filed May 17, 2023 22:17 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 4,760 | $5.60 | $26,656.00 |
DisclosureSEC source: 0001209191-23-030372 · doc4.xml · nonDerivative · entry 1 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 790,159 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:15 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 1,258 | $8.44 | $10,617.52 |
DisclosureSEC source: 0001209191-23-010779 · doc4.xml · nonDerivative · entry 1 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 794,310 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:14 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 404,857 | $0.00 Strike: $8.55 | $0.00 |
DisclosureSEC source: 0001209191-23-007054 · doc4.xml · derivative · entry 4 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 404,857 Underlying: Class A Common Stock · 404,857 shares Expires 2033-02-01 F5 · derivative.exercise_date: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:14 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 2,669 | $8.55 | $22,819.95 |
DisclosureSEC source: 0001209191-23-007054 · doc4.xml · nonDerivative · entry 3 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 795,568 F4 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:14 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 7,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007054 · doc4.xml · nonDerivative · entry 2 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 798,237 F3 · kind: This RSU vested immediately upon the grant date. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:14 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 202,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007054 · doc4.xml · nonDerivative · entry 1 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 790,502 F1 · kind: This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2023 and every three months thereafter. F2 · balance_after: Includes 1,502 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2022. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 23:45 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 1,065 | $11.86 | $12,630.90 |
DisclosureSEC source: 0001209191-22-057704 · doc4.xml · nonDerivative · entry 1 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 586,572 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 22:33 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 1,065 | $12.96 | $13,802.40 |
DisclosureSEC source: 0001209191-22-046462 · doc4.xml · nonDerivative · entry 1 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 587,637 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| May 16, 2022 Filed May 18, 2022 23:17 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 1,069 | $5.67 | $6,061.23 |
DisclosureSEC source: 0001209191-22-030251 · doc4.xml · nonDerivative · entry 1 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588,702 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:07 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 3,914 | $0.00 Strike: $11.40 | $0.00 |
DisclosureSEC source: 0001209191-22-007913 · doc4.xml · derivative · entry 5 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,914 Underlying: Class A Common Stock · 3,914 shares Expires 2032-02-04 Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:07 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 116,684 | $0.00 Strike: $11.40 | $0.00 |
DisclosureSEC source: 0001209191-22-007913 · doc4.xml · derivative · entry 4 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,684 Underlying: Class A Common Stock · 116,684 shares Expires 2032-02-04 F4 · derivative.exercise_date: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:07 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 678 | $11.40 | $7,729.20 |
DisclosureSEC source: 0001209191-22-007913 · doc4.xml · nonDerivative · entry 3 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 589,771 Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:07 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007913 · doc4.xml · nonDerivative · entry 2 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 590,449 F3 · kind: This RSU vested immediately upon the grant date. Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:07 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 58,342 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007913 · doc4.xml · nonDerivative · entry 1 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588,492 F1 · kind: This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2022 and every three months thereafter. F2 · balance_after: Includes 1,388 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on November 22, 2021. Read SEC document |
| February 04, 2022 Filed Apr 28, 2023 20:30 UTC Amendment | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 678 | $11.40 | $7,729.20 |
DisclosureSEC source: 0001209191-23-026036 · doc4a.xml · nonDerivative · entry 3 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 590,380 F2 · balance_after: Includes 1,388 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on November 22, 2021 and 609 shares received pursuant to a pro rata distribution from Catalio Nexus Fund II, LP, of which the Reporting Person was a limited partner (the acquisition of such shares from Catalio was inadvertently excluded from the total shares held in the original Form 4 filing and is exempt pursuant to Rule 16a-9). Read SEC document |
| February 04, 2022 Filed Apr 28, 2023 20:30 UTC Amendment | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026036 · doc4a.xml · nonDerivative · entry 2 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 591,058 F3 · kind: This RSU vested immediately upon the grant date. F2 · balance_after: Includes 1,388 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on November 22, 2021 and 609 shares received pursuant to a pro rata distribution from Catalio Nexus Fund II, LP, of which the Reporting Person was a limited partner (the acquisition of such shares from Catalio was inadvertently excluded from the total shares held in the original Form 4 filing and is exempt pursuant to Rule 16a-9). Read SEC document |
| February 04, 2022 Filed Apr 28, 2023 20:30 UTC Amendment | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 58,342 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026036 · doc4a.xml · nonDerivative · entry 1 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 589,101 F1 · kind: This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2022 and every three months thereafter. F2 · balance_after: Includes 1,388 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on November 22, 2021 and 609 shares received pursuant to a pro rata distribution from Catalio Nexus Fund II, LP, of which the Reporting Person was a limited partner (the acquisition of such shares from Catalio was inadvertently excluded from the total shares held in the original Form 4 filing and is exempt pursuant to Rule 16a-9). Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:09 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionStock Option (Right to Buy) · Derivative | 1,500,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-21-028044 · doc4.xml · derivative · entry 8 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Class A Common Stock · 1,500,000 shares Expires 2030-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the award shall vest incrementally upon satisfaction of certain liquidity events. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:09 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionStock Option (Right to Buy) · Derivative | 820,313 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-21-028044 · doc4.xml · derivative · entry 7 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 820,313 Underlying: Class A Common Stock · 820,313 shares Expires 2030-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:09 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionStock Option (Right to Buy) · Derivative | 1,500,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-21-028044 · doc4.xml · derivative · entry 6 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500,000 shares Expires 2030-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the award shall vest incrementally upon satisfaction of certain liquidity events. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:09 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionStock Option (Right to Buy) · Derivative | 820,313 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001209191-21-028044 · doc4.xml · derivative · entry 5 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 820,313 shares Expires 2030-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:09 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionSeries D Preferred Stock · Derivative | 149,077 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028044 · doc4.xml · derivative · entry 4 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 149,077 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date. F1 · derivative.exercise_date: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. F1 · derivative.expiration_date: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:09 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | OtherClass A Common Stock | 528,762 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028044 · doc4.xml · nonDerivative · entry 3 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 528,762 F1 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:09 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | OtherCommon Stock | 528,762 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028044 · doc4.xml · nonDerivative · entry 2 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:09 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionCommon Stock | 149,077 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028044 · doc4.xml · nonDerivative · entry 1 Secora Michael · CIK 0001855980 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 528,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.